-
Changes in Ryvu’s Management Board
Read More
July 26, 2022 -
Information on a potential supply of shares in connection with the expiration of the lock-up period for shares under the Stock Grant Program
Read More
July 8, 2022 -
Execution of an exclusive license agreement with Exelixis, Inc. to develop novel STING agonist-based targeted cancer therapies
Read More
July 7, 2022 -
Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 30, 2022
Read More
July 1, 2022 -
Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
July 1, 2022 -
Publication of the updated phase 1b clinical and preclinical data for RVU120 and phase 1/2 SEL24 (MEN1703)
Read More
June 10, 2022 -
Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 3, 2022 -
New data from RVU120 and SEL24(MEN1703) programs to be presented at the EHA Hybrid Congress 2022
Read More
May 12, 2022 -
Ryvu Therapeutics to present recent RVU120 and SEL24 (MEN1703) data at ASCO 2022 Annual Meeting
Read More
April 27, 2022 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
April 1, 2022
Report: Current Stock Reports
Title